Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.58 |
| ▸ | MTOR | P42345 | 4/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.58 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856056 | 0.91 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL856846 | 0.90 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL855472 | 0.87 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL855570 | 0.83 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL855812 | 0.82 | PIK3CA (0.64) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL856753 | 0.78 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL10328074 | 0.77 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL10327871 | 0.76 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2675112 | 0.73 | PIK3CA (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL12091786 | 0.73 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885PIK3CD 7/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.